Steven L. Cockrill, Ph.D.
Dr. Cockrill brings over 20 years of biotherapeutic commercialization experience from first-in-human through licensure and post-marketing filing support. His expertise lies in the advancement of various product modalities including traditional biologics (recombinant glycoproteins, monoclonal antibodies, Fc-fusion proteins) from mammalian and microbial expression systems, gene therapies (PEGylated antisense oligonucleotides), and microbiome-based live bacterial therapeutics from the perspective of analytical development, quality control, and oversight of external contract organizations for testing, development, and manufacturing operations.
Prior to his consultancy, Dr. Cockrill served as head of analytical functions (Analytical Development and Quality Control) as Senior Director, Executive Director, and Vice President roles in various virtual and semi-virtual organizations.
His previous responsibilities included leading efforts to develop and optimize analytical strategies and global implementation of technologies to support Amgen's future state aspirations for Quality Control. Prior to his role in Corporate Quality Control, he provided oversight of commercialization activities with respect to late-stage biologic therapeutics as a lead in Analytical Sciences and functional representative on process teams at Amgen.
Before Amgen, he had roles at Sigma-Aldrich Biotechnology and Tanox, supporting method development and characterization of various protein therapeutics.
Dr. Cockrill holds a B.Sc. in Chemistry from the University of York, England and a Ph.D. in Chemistry from Texas A&M University.